RQ 00310941

Drug Profile

RQ 00310941

Alternative Names: 5-HT 2B antagonist - RaQualia

Latest Information Update: 22 Apr 2016

Price : $50

At a glance

  • Originator Pfizer Japan
  • Developer RaQualia Pharma
  • Class Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Irritable bowel syndrome

Most Recent Events

  • 20 Apr 2016 RaQualia receives patent allowance for 5-HT2B in South Korea
  • 22 Feb 2016 Phase-I clinical trials in Irritable bowel syndrome (In healthy volunteers) in United Kingdom (unspecified route) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top